Rifamycin SV 600mg t.i.d. + Rifamycin SV b.i.d. + Placebo + Placebo t.i.d.
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diarrhea-predominant Irritable Bowel Syndrome
Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Trial Timeline
Dec 18, 2017 → Dec 14, 2020
NCT ID
NCT03099785About Rifamycin SV 600mg t.i.d. + Rifamycin SV b.i.d. + Placebo + Placebo t.i.d.
Rifamycin SV 600mg t.i.d. + Rifamycin SV b.i.d. + Placebo + Placebo t.i.d. is a phase 2 stage product being developed by Cosmo Pharmaceuticals for Diarrhea-predominant Irritable Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03099785. Target conditions include Diarrhea-predominant Irritable Bowel Syndrome.
What happened to similar drugs?
0 of 2 similar drugs in Diarrhea-predominant Irritable Bowel Syndrome were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03099785 | Phase 2 | Completed |
Competing Products
3 competing products in Diarrhea-predominant Irritable Bowel Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM060 + Placebo | Astellas Pharma | Phase 3 | 40 |
| YM060 | Astellas Pharma | Phase 3 | 40 |
| Ramosetron | Astellas Pharma | Pre-clinical | 26 |